Answers are grounded in this paper and cite their sources.
The cation substitution-dependent phase transition was used as a strategy to discover new solid solution phosphors and to efficiently tune the luminescence property of divalent europium (Eu 2+ ) in the M 3 (PO 4 ) 2:Eu 2+ (M = Ca/Sr/Ba) quasi-binary sets. Several new phosphors including the greenish-white SrCa 2 (PO 4 ) 2:Eu 2+, the yellow Sr 2 Ca(PO 4 ) 2:Eu 2+, and the cyan Ba 2 Ca(PO 4 ) 2:Eu 2+ were reported, and the drastic red shift of the emission toward the phase transition point was discussed. Different behavior of luminescence evolution in response to structural variation was verified among the three M 3 (PO 4 ) 2:Eu 2+ joins. Sr 3 (PO 4 ) 2 and Ba 3 (PO 4 ) 2 form a continuous isostructural solid solution set in which Eu 2+ exhibits a similar symmetric narrow-band blue emission centered at 416 nm, whereas Sr 2+ substituting Ca 2+ in Ca 3 (PO 4 ) 2 induces a composition-dependent phase transition and the peaking emission gets red shifted to 527 nm approaching the phase transition point. In the Ca 3– x Ba x (PO 4 ) 2:Eu 2+ set, the validity of crystallochemical design of phosphor between the phase transition boundary was further verified. This cation substitution strategy may assist in developing new phosphors with controllably tuned optical properties based on the phase transition.
No takes yet. Share an insight, caveat, or question.
Ji et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: